ライフサイエンスコーパス: anti-HIV drug

1 thioate oligodeoxynucleotides (Sd, potential anti-HIV drugs).

2 m and to develop resistance to the available anti-HIV drugs.

3 RT) is a major target for currently approved anti-HIV drugs.

4 ing minocycline in the class of anticellular anti-HIV drugs.

5 nfluenced by slope and varies by >8 logs for anti-HIV drugs.

6 '-dideoxynucleosides (d4Ns) are FDA-approved anti-HIV drugs.

7 e transcriptase inhibitors, a major class of anti-HIV drugs.

8 for development of an entirely new class of anti-HIV drugs.

9 y serve as an important target for designing anti-HIV drugs.

10 osis, HCV genotype, and exposure to specific anti-HIV drugs.

11 nd has great potential as a novel target for anti-HIV drugs.

12 ly being targeted for the development of new anti-HIV drugs.

13 ereby contribute to the clinical efficacy of anti-HIV drugs.

14 be used in the development of more effective anti-HIV drugs.

15 cation of a new class of orally bioavailable anti-HIV drugs.

16 Anti-HIV drugs, alone or in combination, did not materia

17 sponsible for the resistance of HTLV-1 PR to anti-HIV drugs are identified.

18 The use of anti-HIV drugs as cancer treatments is not new.

19 explain the development of resistance to the anti-HIV drug AZT.

20 rovide a novel target for the development of anti-HIV drugs based on the concept of trapping a nonnat

21 In this article, we characterize the anti-HIV drug candidate 3-O-(3',3'-dimethylsuccinyl) bet

22 e inhibitors (NRTIs), the most commonly used anti-HIV drugs, compete against cellular dNTPs for incor

23 Griffithsin, and to T-20 and maraviroc, two anti-HIV drugs currently in clinical use.

24 s: the Data Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study equation.

25 The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study has developed predictive ri

26 rom the Data collection on Adverse events of anti-HIV Drugs (D:A:D) study were followed up from March

27 rom the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study with >/=3 estimated glomeru

28 e are at least three high priority goals for anti-HIV drug delivery (DD) research: (1) to prevent new

29 iption, it represents a promising target for anti-HIV drug design.

30 n and represents a very promising target for anti-HIV drug design.

31 therefore represents a promising target for anti-HIV drug design.

32 n urgent need for new ways of thinking about anti-HIV drug development, and accordingly novel viral a

33 complex could become an important target for anti-HIV drug development, where a drug could exert its

34 d from this study may be important for novel anti-HIV drug development.

35 V-1 cell entry has long been a major goal of anti-HIV drug development.

36 s of Nef signaling and potential targets for anti-HIV drug discovery.

37 ost protein complex as a rational target for anti-HIV drug discovery.

38 Previously, we found that the anti-HIV drug efavirenz (EFV) can pharmacologically acti

39 validated for HIV by the FDA approval of the anti-HIV drug enfuvirtide.

40 more lipophilic than the currently approved anti-HIV drugs for better blood-brain barrier penetratio

41 Although a number of useful anti-HIV drugs have been approved for use in patients, t

42 Thus, anti-HIV drugs have little or no activity against P. car

43 V-infection, Coc exposure and treatment with anti-HIV drug i.e., Tef, and Coc antagonist i.e., RA.

44 -dideoxyadenosine (F-ddA, lodenosine), a new anti-HIV drug, in human lymphocytes by HPLC using fluore

45 ading capacity of hydrophobic anticancer and anti-HIV drugs, indicating promising applications in HIV

46 eficiency virus (HIV) leading to escape from anti-HIV drugs is the greatest challenge to the treatmen

47 egion, is the first member of a new class of anti-HIV drugs known as HIV fusion inhibitors.

48 ion of viral replication achieved by current anti-HIV drugs, many patients fail treatment, often with

49 ancer drugs with multiple effects, and other anti-HIV drugs might hold similar promise.

50 deplete host-cell dTTP, unlike conventional anti-HIV drug monotherapy directed solely at viral enzym

51 ports of the susceptibility of P. carinii to anti-HIV drugs on the basis of in vitro testing only.

52 Anti-HIV drugs or virus-neutralizing monoclonal antibodi

53 vir increases plasma concentrations of other anti-HIV drugs oxidized by CYP3A4 thereby improving clin

54 wledge accumulated during the development of anti-HIV drugs, particularly in overcoming drug resistan

55 he IN, which is a new target in the field of anti-HIV drug research.

56 ations made during the Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN)/WHO meeting (Oc

57 nhibitor ritonavir as a pharmacoenhancer for anti-HIV drugs revolutionized the treatment of HIV infec

58 in the Data Collection on Adverse Events of Anti-HIV Drugs study without HCV or HBV coinfection were

59 RP4) functions as a cellular efflux pump for anti-HIV drugs, such as 9-(2-phoshoenylmethoxyethyl) ade

60 -dimensional nanomaterials and the design of anti-HIV drugs targeting (dis)assembly and biocompatible

61 briefly discuss several actin pathway-based anti-HIV drugs that are currently in development or test

62 Thus, dCA defines a unique class of anti-HIV drugs that may inhibit viral production from st

63 ut the source of the sequence sample and the anti-HIV drug treatment history of the individual from w

64 f anemia should be considered when examining anti-HIV drug treatment regimens in HIV-1C-predominant a

65 Twelve anti-HIV drugs were analyzed for their effects against r

66 the nucleoside inhibitors used clinically as anti-HIV drugs which target HIV-1 reverse transcriptase

67 cs were regulated by cognate nucleotides and anti-HIV drugs, which stabilized and destabilized the po

68 control point to the need for new classes of anti-HIV drugs with different modes of action.

69 Anti-HIV drugs work; so far drug therapy has saved more